Amivantamab plus chemo vs. standard chemo for left-sided colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial compares a new combination (amivantamab plus chemotherapy) with the standard treatment (cetuximab plus chemotherapy) as the first therapy for people with left-sided colorectal cancer that has spread. The goal is to see which approach works better when the tumor has no mutations in the KRAS, NRAS, or BRAF genes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your colorectal cancer is on the left side of your colon or rectum and has spread or cannot be removed with surgery.
- Your tumor does not have changes (mutations) in the KRAS, NRAS, or BRAF genes — this is called 'wild-type'.
- You have not had any previous treatment for colorectal cancer that has spread. (If you had chemo or radiation for an earlier stage, it must have ended more than 12 months ago.)
- You have not taken any medicines that target EGFR, MET, or VEGF (like cetuximab or bevacizumab).
- You are well enough to perform daily activities (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding amivantamab to standard FOLFIRI chemotherapy for people with certain types of colorectal cancer that have already been treated once. It aims to see if this combination works better than another common treatment (cetuximab or bevacizumab plus FOLFIRI).
This trial tests a combination of targeted radiation therapy, an immune-boosting drug, and two chemotherapy drugs for colorectal cancer that has spread or come back after two rounds of prior treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new drug called Pumitamig combined with chemotherapy against standard bevacizumab plus chemotherapy for people with advanced colorectal cancer that cannot be surgically removed and hasn't been treated yet. The goal is to see which combination works better and is safer.
This trial tests whether adding the drug amivantamab to usual treatments helps people with advanced head and neck cancer that has come back or spread. It compares the combination to standard care alone.
This Phase 1/2 study tests amivantamab alone or combined with standard chemotherapy to treat advanced or metastatic colon or rectal cancer. You may be able to join if your tumor has the right genetic profile (typically “wild-type” for certain genes and no HER2 amplification) and your cancer has measurable or biopsy-able lesions.
This trial is for people with advanced colorectal cancer that has gotten worse after treatment with anti-EGFR therapy. It tests a combination of amivantamab (a targeted drug) and FOLFIRI (a chemotherapy regimen) as a second-line treatment to see if it can help shrink tumors or slow the cancer's growth.
Hear when a new Colorectal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.